🔍

TORNTPHARM - Torrent Pharma.

📊 NSE: TORNTPHARM 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 14:26

📢 Recent Corporate Announcements

Torrent Pharma to Hold Institutional Investor Meetings in Singapore, HK, and London

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 07:26 PM

Torrent Pharmaceuticals has announced a series of international institutional investor meetings scheduled from March 2 to March 12, 2026. The company will engage with investors in Singapore (March 2-4), Hong Kong (March 5-6), and London (March 9-12). These interactions will include both group and one-on-one formats to discuss the company's performance and outlook. This is a routine regulatory disclosure under SEBI LODR regulations to ensure transparency with the global investment community.

Meetings scheduled across three major global financial hubs: Singapore, Hong Kong, and London.
The engagement period spans 11 days from March 2, 2026, to March 12, 2026.
Interaction formats include both group sessions and one-on-one meetings with institutional investors.
Disclosure made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).

💡 No immediate action is required as this is a routine investor relations event. Investors should monitor for any investor presentations or transcripts released post-meetings for insights into growth strategy.

Torrent Pharma Releases Q3 FY25-26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 06:46 PM

Torrent Pharmaceuticals has officially released the transcript of its conference call with analysts and investors regarding the financial results for Q3 and the nine months ended December 31, 2025. The filing follows the initial earnings announcement made on February 2, 2026, providing a detailed record of management's commentary and responses to investor queries. This document is a standard regulatory requirement under SEBI LODR Regulations to ensure transparency. Investors can access the full discussion on the company's website to gain deeper insights into operational performance.

Official transcript for Q3 and 9M FY25-26 earnings call is now publicly available.
Filing complies with Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The transcript covers management's detailed discussion on financial performance for the period ending December 31, 2025.
The document is hosted on the company's official investor relations portal for public access.

💡 Investors should review the transcript for specific management guidance on domestic market growth and margin sustainability. No immediate action is required as this is a routine administrative disclosure.

Torrent Pharma Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 07:45 PM

Torrent Pharmaceuticals has officially released the audio recording of its conference call with analysts and investors regarding the financial results for the quarter and nine months ended December 31, 2025. This filing is a standard regulatory requirement under SEBI LODR Regulations to ensure transparency in management communications. The recording allows stakeholders to hear direct commentary on the company's performance and strategic outlook. The call follows the initial financial results announcement previously disclosed on February 2, 2026.

Audio recording for Q3 and 9M FY26 results is now available on the company website.
The disclosure is made pursuant to Regulation 30(6) of SEBI (LODR) Regulations, 2015.
The conference call follows the financial results declared on February 2, 2026.
Provides access to management's detailed discussion on operational and financial metrics.

💡 Investors should review the audio recording for qualitative insights into the company's domestic market growth and margin guidance. This is a routine compliance update and does not necessitate any immediate investment action.

Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:10 PM

Torrent Pharmaceuticals reported a strong performance for Q3 FY2025-26, with net profit increasing 19% year-on-year to ₹577 crores. Revenue from operations grew to ₹2,599 crores compared to ₹2,377 crores in the same quarter last year. The company's board declared a substantial interim dividend of ₹29 per share (580% of face value), with a payout expected by March 6, 2026. For the nine-month period, the company has shown consistent growth, with total profit reaching ₹1,725 crores against ₹1,414 crores in the previous year.

Net profit for Q3 FY26 rose 19% YoY to ₹577 crores from ₹485 crores.
Revenue from operations increased to ₹2,599 crores, up from ₹2,377 crores in Q3 FY25.
Declared an interim dividend of ₹29 per equity share (580% of face value).
Earnings Per Share (EPS) for the quarter improved to ₹17.04 from ₹14.33 YoY.
Nine-month total income grew to ₹7,937 crores compared to ₹7,266 crores in the prior year period.

💡 Investors should consider the strong bottom-line growth and healthy dividend payout as positive indicators of operational efficiency. The stock remains a robust pick for those seeking a combination of growth and regular income.

Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:06 PM

Torrent Pharmaceuticals reported a strong performance for Q3 FY26, with revenue from operations growing to ₹2,599 crore compared to ₹2,377 crore in the same quarter last year. Net profit saw a significant jump of approximately 19% year-on-year, reaching ₹577 crore. The company also announced a substantial interim dividend of ₹29 per equity share, representing 580% of the face value. For the nine-month period ended December 2025, the company maintained momentum with a net profit of ₹1,725 crore against ₹1,414 crore in the previous year.

Revenue from operations increased by 9.3% YoY to ₹2,599 crore in Q3 FY26
Net profit for the quarter grew by 19% YoY to ₹577 crore from ₹485 crore
Board declared an interim dividend of ₹29 per share (580%) with payment expected by March 6, 2026
Basic and Diluted EPS improved to ₹17.04 for the quarter compared to ₹14.33 in the previous year's quarter
9M FY26 net profit stands at ₹1,725 crore, showing a robust 22% growth over 9M FY25

💡 Investors should view the consistent double-digit profit growth and high dividend payout as a sign of strong operational health. The stock remains a solid hold for long-term investors looking for steady earnings growth and dividend income.

Torrent Pharma Q3 FY26 Revenue Grows 18% YoY to Rs 3,303 Crore

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:02 PM

Torrent Pharmaceuticals reported a strong 18% year-on-year growth in total revenue for Q3 FY26, reaching Rs 3,303 crore compared to Rs 2,809 crore in the previous year. The growth was broad-based across all geographies, with the Brazil market leading at 27% growth and the US market growing by 19%. The core India business, which remains the largest contributor, grew by 14% to Rs 1,798 crore. For the nine-month period ending December 2025, the company achieved a total revenue of Rs 9,783 crore, marking a 14% increase over the same period last year.

Total Q3 FY26 revenue increased 18% YoY to Rs 3,303 crore from Rs 2,809 crore
Brazil business recorded the highest regional growth of 27% YoY, reaching Rs 371 crore
India domestic revenue grew 14% YoY to Rs 1,798 crore, maintaining its dominant share
US revenue saw a significant 19% YoY increase to Rs 321 crore
YTD Dec 25 total revenue stands at Rs 9,783 crore, up 14% from Rs 8,557 crore in YTD Dec 24

💡 Investors should take note of the robust double-digit growth across all major markets, indicating strong operational momentum. The stock remains a key pick in the pharma sector due to its high domestic exposure and improving international performance.

Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:00 PM

Torrent Pharmaceuticals reported a solid performance for Q3 FY26, with revenue from operations growing 9.3% year-on-year to ₹2,599 crore. Net profit saw a significant jump of 19%, reaching ₹577 crore compared to ₹485 crore in the same quarter last year. The board has rewarded shareholders with a substantial interim dividend of ₹29 per equity share. Despite a slight sequential dip in revenue compared to Q2 FY26, the year-to-date profit growth remains robust at 22%.

Revenue from operations increased to ₹2,599 crore, up 9.3% YoY from ₹2,377 crore.
Net Profit for the quarter stood at ₹577 crore, representing a 19% YoY growth.
Interim dividend of ₹29 per share (580%) announced with a payment date around March 6, 2026.
Nine-month FY26 net profit reached ₹1,725 crore, a 22% increase over the previous year's ₹1,414 crore.
Basic EPS improved to ₹17.04 for the quarter from ₹14.33 in the year-ago period.

💡 Investors should find the strong double-digit profit growth and high dividend payout encouraging, reflecting healthy cash flows. The stock remains a solid pick for those seeking stability in the domestic-focused pharmaceutical space.

Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 13 Feb 2026, 05:00 PM

Torrent Pharmaceuticals has declared an interim dividend of ₹29 per share (580% of face value) for FY 2025-26. The company reported a strong Q3 FY26 performance with net profit rising 19% year-on-year to ₹577 crores, up from ₹485 crores in the same quarter last year. Revenue for the quarter grew to ₹2,599 crores, reflecting steady operational growth. The dividend is expected to be paid to shareholders on or around March 6, 2026.

Declared an interim dividend of ₹29 per equity share of ₹5 face value
Q3 FY26 Net Profit grew 19% YoY to ₹577 crores vs ₹485 crores in Q3 FY25
Total Revenue from operations for Q3 FY26 rose to ₹2,599 crores from ₹2,377 crores YoY
Nine-month (9M FY26) Net Profit reached ₹1,725 crores compared to ₹1,414 crores in 9M FY25
Dividend payment is scheduled to be dispatched on or around March 6, 2026

💡 Investors should consider the healthy dividend payout and double-digit profit growth as a sign of strong cash flow and operational stability. The stock remains a solid pick for long-term portfolios seeking a mix of growth and regular income.

Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 13 Feb 2026, 04:53 PM

Torrent Pharmaceuticals has declared a substantial interim dividend of ₹29 per equity share (580% of face value) for the financial year 2025-26. The company reported a strong Q3 performance with standalone net profit rising 19% year-on-year to ₹577 crore, driven by a 9.3% growth in total revenue to ₹2,599 crore. For the nine-month period ended December 2025, the company's net profit saw a significant 22% increase to ₹1,725 crore. The dividend is expected to be paid to shareholders on or around March 6, 2026.

Declared an interim dividend of ₹29 per equity share of ₹5 each (580% payout)
Standalone Q3 net profit increased by 19% YoY to ₹577 crore from ₹485 crore
Total revenue for Q3 FY26 grew to ₹2,599 crore compared to ₹2,377 crore in Q3 FY25
9-month standalone net profit reached ₹1,725 crore, up from ₹1,414 crore in the previous year
Dividend payment or dispatch is scheduled to be completed by March 6, 2026

💡 Investors should maintain a positive outlook given the strong 19% profit growth and healthy dividend payout. The stock remains attractive for long-term investors seeking consistent yield and steady earnings expansion in the pharmaceutical sector.

Torrent Pharma Schedules Multiple Institutional Investor Meetings for February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 09:42 PM

Torrent Pharmaceuticals has announced a series of investor interactions scheduled between February 16 and February 24, 2026. The company will participate in institutional meetings in Mumbai followed by two major industry conferences: Kotak's 'Chasing Growth 2026' and IIFL's 'Enterprising India'. These sessions will include both group and one-on-one formats. Such meetings are standard practice for management to engage with the investment community regarding business strategy and outlook.

Institutional investor meetings scheduled in Mumbai from February 16 to February 19, 2026.
Participation in Kotak - Chasing Growth 2026 Investor Conference on February 23, 2026.
Participation in IIFL - Enterprising India Investor Conference on February 24, 2026.
Meetings will be conducted in both group and one-on-one formats.
The schedule is subject to change based on exigencies from either the company or investors.

💡 No immediate action is required as this is a routine regulatory disclosure. Investors should watch for any investor presentations or transcripts released post-event for updates on the company's growth trajectory.

Torrent Pharma Completes JB Chemicals Stake Acquisition, Reaches 48.80% Holding

🟢 POSITIVE ⭐ 9/10

M&A 📅 03 Feb 2026, 10:00 PM

Torrent Pharmaceuticals has successfully completed its planned acquisition of J.B. Chemicals & Pharmaceuticals Limited shares. On February 3, 2026, the company acquired a final tranche of 92,490 shares (0.06%) from an employee, fulfilling all obligations under the Share Purchase Agreements dated June and July 2025. Following this transaction, Torrent Pharma's total stake in JB Chemicals stands at 48.80%, representing 7,83,57,892 equity shares. This marks the conclusion of a major strategic investment process initiated in 2025.

Acquired 92,490 equity shares (0.06% stake) from a JB Chemicals employee on February 3, 2026
Total aggregate holding in JB Chemicals reached 7,83,57,892 equity shares
Final ownership stake stands at 48.80% of JB Chemicals on a fully diluted basis
Completion of all acquisitions under the Share Purchase Agreements dated June 29 and July 3, 2025

💡 Investors should view this as a significant strategic consolidation that strengthens Torrent's market position; focus on upcoming quarterly results to see the impact of JB Chemicals' integration on the consolidated bottom line.

Torrent Pharma Sets Feb 19, 2026, as Record Date for Interim Dividend

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 03 Feb 2026, 06:24 PM

Torrent Pharmaceuticals has fixed February 19, 2026, as the record date to determine shareholder eligibility for a potential interim dividend. The formal declaration of this dividend is subject to approval at the Board of Directors meeting scheduled for February 13, 2026. This announcement pertains to equity shares with a face value of ₹5 each. Investors holding the stock on the record date will be entitled to the payout if approved.

Record date for interim dividend eligibility is Thursday, February 19, 2026.
Board meeting to consider and declare the dividend is scheduled for February 13, 2026.
The dividend applies to equity shares with a face value of ₹5 per share.
The notification is issued under Regulation 42 of SEBI Listing Regulations.

💡 Investors seeking to receive the dividend should ensure they purchase or hold shares before the ex-dividend date. Monitor the February 13 board meeting outcome for the specific dividend amount per share.

Torrent Pharma Schedules Q3 FY26 Earnings Conference Call for February 13, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 02 Feb 2026, 05:47 PM

Torrent Pharmaceuticals Limited has announced its post-quarterly financial results conference call scheduled for February 13, 2026, at 06:30 P.M. IST. The management will discuss the company's financial performance for the third quarter ended December 31, 2025. This call provides an opportunity for investors and analysts to gain insights into the company's operational trends and future outlook. The company has provided universal dial-in numbers and international toll-free access for global participants.

Conference call scheduled for February 13, 2026, at 18:30 IST.
Focus on financial performance for the quarter ended December 31, 2025.
Universal dial-in numbers provided: +91 22 6280 1439 and +91 22 7115 8803.
International toll-free numbers available for USA (18667462133) and UK (08081011573).
Diamond Pass registration link provided for priority access to the call.

💡 Investors should monitor the official earnings release prior to the call and listen to management commentary for updates on domestic growth and export margins.

Torrent Pharmaceuticals to Shift Registered Office within Ahmedabad Effective Jan 29, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jan 2026, 06:34 PM

Torrent Pharmaceuticals has announced a change in its registered office address within the city of Ahmedabad. The Board of Directors approved the relocation from 'Torrent House' on Ashram Road to 'Avirat' on Thaltej Shilaj Road during their meeting on January 27, 2026. This administrative shift is effective from January 29, 2026. Since the relocation is within the local limits of the same city, it has no impact on business operations or financial standing.

Registered office shifting from Torrent House, Ashram Road to Avirat, Thaltej Shilaj Road
Relocation is effective from January 29, 2026
The move remains within the local limits of Ahmedabad city
Board of Directors accorded consent for the shift on January 27, 2026

💡 No action is required from investors as this is a routine administrative update. Shareholders should note the new address for any future physical correspondence.

Torrent Pharma's Dahej Facility Clears USFDA Inspection with Zero Observations

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 23 Jan 2026, 06:37 PM

Torrent Pharmaceuticals has announced the successful conclusion of a USFDA inspection at its Dahej manufacturing facility. The audit took place from January 19 to January 23, 2026, and resulted in zero observations. This clean report signifies full compliance with global manufacturing standards and removes potential regulatory hurdles for the site. Such outcomes are critical for pharmaceutical companies to maintain and expand their product portfolio in the lucrative US market.

USFDA inspection of the Dahej facility concluded on January 23, 2026
The audit resulted in zero observations, meaning no Form 483 was issued
Inspection period spanned five days from January 19 to January 23, 2026
Successful clearance ensures continued compliance for exports to the US market

💡 This is a significant positive development that de-risks the company's US-led growth strategy. Investors should maintain confidence in the company's manufacturing quality and regulatory standing.

View All TORNTPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenues grew 7% to INR 11,516 Cr in FY25. In Q2 FY26, India business grew 12% to INR 1,820 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%. US business grew 26% in Q2 FY26, while Brazil grew 21% (13% in constant currency). Germany grew 5% in Q2 FY26, though it declined 5% in constant currency due to supply disruptions.

Geographic Revenue Split

India is the largest market contributing 55% of total revenue (INR 6,393 Cr in FY25). Branded markets collectively accounted for 73% of overall revenue in Q2 FY26. Other key regions include Brazil, Germany, and the USA.

Profitability Margins

Gross Profit margin improved to 76% in FY25 from 75% in FY24. Net profit margin (adjusted for exceptions) stood at 16.6% in FY25 compared to 15.4% in FY24. Profit After Tax (PAT) grew 15.4% to INR 1,911 Cr in FY25 from INR 1,656 Cr in FY24.

EBITDA Margin

Operating EBITDA margin was 32% in FY25 (INR 3,721 Cr), up from 31% (INR 3,368 Cr) in FY24. For Q2 FY26, the EBITDA margin further improved to 32.8% (INR 1,083 Cr), representing a 15% YoY growth in EBITDA value.

Capital Expenditure

Total R&D expenditure, including capital expenses, was INR 431.53 Cr in FY25. The company also maintains an enabling resolution to raise funds through a Qualified Institutional Placement (QIP) for large acquisitions like JB Chemicals.

Credit Rating & Borrowing

The company reduced borrowings by INR 911 Cr in FY25. Net leverage (Net Debt to EBITDA) improved from 0.62x in FY25 to 0.45x in Q2 FY26. ICRA notes that leverage may rise to ~2.2x by March 2027 following the JB Chemicals acquisition, which is being funded entirely through debt.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (API) and other formulation materials are the primary inputs. While specific % of total cost per material is not disclosed, Gross Profit margin of 76% indicates raw material costs are approximately 24% of revenue.

Import Sources

Sourced from both domestic and foreign suppliers to support global manufacturing operations across India, Germany, and Brazil.

Key Suppliers

Not specifically named, but the company utilizes both in-house API manufacturing and third-party vendors. A disruption at a specific third-party supplier in Germany caused a 5% constant currency revenue decline in that market in Q2 FY26.

Capacity Expansion

The company operates key manufacturing facilities at Dahej and Indrad. Future growth is tied to the integration of JB Chemicals' manufacturing operations and supply chains to capture cost synergies.

Raw Material Costs

Raw material costs are managed through alternate sourcing strategies and vertical integration. Gross profit increased by 9% YoY to INR 8,740 Cr in FY25, reflecting efficient procurement despite a 7% revenue increase.

Manufacturing Efficiency

Efficiency is driven by increasing operating leverage and cost control. Operating margins improved to 32.2% in 9M FY25 from 29.5% in FY23 due to better capacity utilization and branded market focus.

Logistics & Distribution

Distribution is managed through a global footprint; logistics optimization and rate contracts with vendors are used to rationalize costs.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth is driven by the acquisition of JB Chemicals (INR 25,689 Cr valuation) to gain scale in cardiology and gastro segments. In India, the company targets outperforming the IPM through its chronic business (currently growing at 13%). US growth is expected to accelerate following USFDA EIR/VAI status at Dahej and Indrad, enabling more than the previous 2 launches per year.

Products & Services

Branded and generic pharmaceutical formulations in therapeutic segments including Cardiovascular (CVS), Gastrointestinal (GI), Central Nervous System (CNS), and vitamins/nutrients.

Brand Portfolio

Torrent Pharma, Heumann Pharma (Germany), and soon-to-be-integrated brands from JB Chemicals and Pharmaceuticals.

New Products/Services

New launches in India and the US are key drivers; US growth of 26% in Q2 FY26 was significantly aided by new product volume and market share gains.

Market Expansion

Expansion is focused on branded generic markets (India, Brazil, SE Asia) and strengthening the German tender business. The JB Chemicals acquisition expands the footprint in India and South Africa.

Market Share & Ranking

Torrent is the 5th largest player in the Indian pharmaceutical market. It has achieved target market shares in new US launches.

Strategic Alliances

Acquisition of a 46.39% stake in JB Chemicals from KKR for INR 11,917 Cr, followed by a mandatory open offer for 26% and an eventual merger.

🌍 External Factors

Industry Trends

The industry is shifting toward branded generics and chronic therapies to ensure stable cash flows. Torrent is positioned as a leader in this shift, with 73% of revenue from branded markets.

Competitive Landscape

Competes with large Indian pharma players and global generic companies. Competition in the US generics market remains intense with persistent price erosion.

Competitive Moat

Moat is built on a strong field force in India/Brazil, high entry barriers in chronic segments, and a proven track record of integrating acquisitions. These are sustainable due to the long-term nature of chronic prescriptions.

Macro Economic Sensitivity

Sensitive to healthcare spending trends and regulatory changes in India and Brazil. Inflation impacts SG&A expenses, which were INR 4,438 Cr (39% of revenue) in FY25.

Consumer Behavior

Increasing demand for chronic disease management (cardiac, gastro) drives steady volume growth in the India business.

Geopolitical Risks

Operations in Russia (Zao Torrent Pharma) and other emerging markets expose the company to regional political instability and trade barriers.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA manufacturing standards (cGMP) and price controls (DPCO in India). Dahej and Indrad facilities are currently under VAI (Voluntary Action Indicated) status.

Environmental Compliance

The company has instituted an ESG framework with four pillars: responsible consumption, practices, communication, and supply chain. It carries significant cyber security insurance.

Taxation Policy Impact

Effective tax rate was approximately 28.5% in FY25 (INR 762 Cr tax on INR 2,673 Cr PBT). The company faces potential tax exposure from cross-border transactions and varying international laws.

Legal Contingencies

Ongoing product liability litigation in the US regarding Losartan and Valsartan. One pending complaint from the Curatio merger was also noted.

⚠️ Risk Analysis

Key Uncertainties

Integration risk of the JB Chemicals acquisition (INR 25,689 Cr value) is a medium-term uncertainty. USFDA regulatory status of manufacturing plants can impact 10-15% of revenue if escalations occur.

Geographic Concentration Risk

High concentration in India (55% of revenue). Any regulatory change in the Indian Pharmaceutical Market (IPM) significantly impacts the consolidated profile.